A Human Pan-Cancer System Analysis of Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase 3 (PLOD3)

• Published in: International journal of molecular sciences 2021-09, Vol.22 (18), p.9903
• Main Authors: Gong, Siming, Duan, Yingjuan, Wu, Changwu, Osterhoff, Georg, Schopow, Nikolas, Kallendrusch, Sonja
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Algorithms; Annotations; CD8 antigen; Collagen; Colon; Copy number; Datasets; Endometrial cancer; Endometrium; enrichment analysis; Esophagus; Fibroblasts; Gene expression; Gene Expression Regulation, Neoplastic; Gene Ontology; Gene Regulatory Networks; Genomes; Genotypes; Humans; immune infiltration; Immune system; Immunohistochemistry; Immunology; Ketoglutaric acid; Kinases; Lung cancer; Lymphocytes; Lymphocytes T; Lymphocytes, Tumor-Infiltrating - immunology; Lysine; Medical prognosis; Melanoma; Metastases; Metastasis; Microsatellite Instability; Molecular modelling; Mutation; Mutation - genetics; Neoplasms - enzymology; Neoplasms - genetics; Neoplasms - immunology; Neoplasms - pathology; Ovarian cancer; pan-cancer; PLOD3; Procollagen; Procollagen-lysine 5-dioxygenase; Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase - metabolism; prognosis; Prostate cancer; Protein expression; Proteins; Soft tissues; Survival; Survival Analysis; Systems analysis; tumor; Tumors; Uterus
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms22189903

The overexpression of the enzymes involved in the degradation of procollagen lysine is correlated with various tumor entities. Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (PLOD3) expression was found to be correlated to the progression and migration of cancer cells in gastric, lung and prostate cancer. Here, we analyzed the gene expression, protein expression, and the clinical parameters of survival across 33 cancers based on the Clinical Proteomic Tumor Analysis Consortium (CPTAC), function annotation of the mammalian genome 5 (FANTOM5), Gene Expression Omnibus (GEO), Genotype-Tissue Expression (GTEx), Human Protein Atlas (HPA) and The Cancer Genome Atlas (TCGA) databases. Genetic alteration, immune infiltration and relevant cellular pathways were analyzed in detail. PLOD3 expression negatively correlated with survival periods and the infiltration level of CD8 T cells, but positively correlated to the infiltration of cancer associated fibroblasts in diverse cancers. Immunohistochemistry in colon carcinomas, glioblastomas, and soft tissue sarcomas further confirm PLOD 3 expression in human cancer tissue. Moreover, amplification and mutation accounted for the largest proportion in esophageal adenocarcinoma and uterine corpus endometrial carcinoma, respectively; the copy number alteration of PLOD3 appeared in all cancers from TCGA; and molecular mechanisms further proved the effect of PLOD3 on tumorigenesis. In particular, PLOD3 expression appears to have a tumor immunological effect, and is related to multiple immune cells. Furthermore, it is also associated with tumor mutation burden and microsatellite instability in various tumors. PLOD3 acts as an inducer of various cancers, and it could be a potential biomarker for prognosis and targeted treatment.